Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Publisher's Note: There is a Blood Commentary on this article in this issue.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2019-01, Vol.133 (5), p.494-497
Hauptverfasser:	Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trněný, Marek, Mulligan, Stephen P., Mey, Ulrich J.M., Trunzer, Kerstin, Fingerle-Rowson, Günter, Humphrey, Kathryn, Stilgenbauer, Stephan, Böttcher, Sebastian, Brüggemann, Monika, Hallek, Michael, Kneba, Michael, van Dongen, Jacques J.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chlorambucil - therapeutic use Comorbidity Humans Letter to Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology Middle Aged Neoplasm, Residual - diagnosis Neoplasm, Residual - drug therapy Neoplasm, Residual - epidemiology Prognosis Prospective Studies Rituximab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Publisher's Note: There is a Blood Commentary on this article in this issue.
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood-2018-03-839688